ABBVIE WKN: A1J84E ISIN: US00287Y1091 Forum: Aktien Thema: Hauptdiskussion

@Kursbeschleuniger Scheint mir ein guter EK zu sein. Denke bei 70 gäbe es eine starke Unterstützung. Neben den hoffentlich guten Zahlen wird sicherlich auch der Ausblick eine Rolle spielen wie es hier weiter geht. Was ich hier bisher gelesen habe klingt unglaublich stark

Welche Titel lohnen sich deiner Meinung nach noch?

Dachte so an 20 Stück.

@NeulingAktien-gute Wahl

Du darfst ;) ich habe immer wieder zugekauft und jetzt genau 100 Stück zu 66.- werde noch bei Kursschwäche auf ca 10.000.- Gesamtinvestition erhöhen.

Darf ich fragen zu welchem Kurd du drin bist@Kursbeschleuniger?

Bin seit Donnerstag auch dabei und bin begeistert von den Möglichkeiten hier.. Sollte es wider Erwarten nochmal eine Rückkehr in Richtung 70 EUR geben, dann verdoppele ich meine Position ✌️

Werde hier wohl auch reingehen

Letztes Jahr im Januar schoss Sie nach den Zahlen enorm nach oben.Mit guten Zahlen muss man dieses Mal sicher auch wieder rechnen.Aber sicher ist nur eins: der Kurs sinkt oder steigt ;) Divipolitik der Firma ist aber super!

Glaube aber nicht dass sie noch viel tiefer fällt.War auch schon über 90..da geht sie früher oder später sicher auch wieder hin

Bin seit 2 Jahren investiert.Aber ich denke es ist jetzt auch nicht zu spät.Mit dieser Aktie macht man nichts falsch,auch wenn’s mal bissl volatil sein sollte

Wenn ich das alles so lese, dann frage ich mich tatsächlich warum ich nicht noch viel früher eingestiegen bin

The magic number There's one number that investors will want to pay special attention to: $35 billion. That's the minimum level of risk-adjusted sales that AbbVie projects it will generate from drugs other than Humira by 2025. By comparison, AbbVie's total revenue in 2017 including Humira was $28.2 billion. Some might question whether AbbVie can achieve that goal. Skepticism certainly is higher now than in the past after cancer drug Rova-T flopped in clinical studies. But the prospects for AbbVie's other drugs and pipeline candidates discussed by Gonzalez and Severino don't seem to be just pie in the sky. AbbVie should be able to continue doing what it's been doing since being spun off in 2013: deliver revenue growth, deliver earnings growth, and deliver a steadily increasing dividend.

3. Time is on its side It's also important to remember that Humira isn't going away anytime soon. Severino stated that AbbVie expects the drug to remain at the top of the immunology market through 2022. That's in line with the thinking from market research company EvaluatePharma, which projects that Humira will remain the top-selling drug in the world through 2024. Although Humira is being challenged by biosimilars in Europe, AbbVie continues to state that there probably won't be direct biosimilar competition in the U.S. until 2023. That gives the company plenty of time for its other drugs and pipeline candidates to ramp up. Gonzalez also said that Humira's sales should continue to grow in the U.S., although he acknowledged that the growth rates have moderated and will continue to do so. He stated that Humira has been "a phenomenal story" and will "continue to be an important growth story" for AbbVie.

2. Blockbuster pipeline candidates Another key reason behind AbbVie's confidence is its pipeline, especially in the area of immunology. Severino stated that AbbVie will "evolve from a single product to a portfolio of therapies" in immunology over the next few years. The first immunology product likely to join Humira is risankizumab. An FDA approval decision for the drug as a treatment for psoriasis is expected by late April 2019. Risankizumab could soon be followed by upadacitinib. AbbVie expects an FDA decision on the drug as a treatment for rheumatoid arthritis in the second half of the year. AbbVie is also pursuing additional indications for both drugs. The company thinks that risankizumab and upadacitinib will be best-in-class therapies that together generate $10 billion or more in incremental annual sales by 2025. In addition, Severino said that the company's neuroscience pipeline candidates should begin contributing to growth by the middle of the next decade. AbbVie's pipeline includes a late-stage candidate targeting Parkinson's disease as well as experimental Alzheimer's disease and multiple sclerosis drugs in earlier-stage clinical studies.

A strong lineup beyond Humira Michael Severino addressed the threat to Humira head-on in his presentation at the J.P. Morgan conference. His first response to the impact of biosimilar competition was to point out the strong growth and future prospects for two other AbbVie drugs, Imbruvica and Venclexta. Severino noted that the two hematology drugs currently represent a $4 billion franchise with double-digit percentage sales growth. He said that AbbVie expects Imbruvica and Venclexta combined will generate over $9 billion of risk-adjusted incremental annual sales by 2025. In addition, Severino singled out a couple of other current products, Orilissa (elagolix) and Mavyret. Orilissa was approved by the FDA last year for the treatment of endometriosis, an indication for which no new treatment has been introduced in decades. AbbVie plans to file for approval of the drug in treating uterine fibroids later this year. The company thinks that Orilissa will contribute upwards of $2 billion in incremental annual risk-adjusted sales by 2025. Rick Gonzalez acknowledged that Mavyret won't be "a big growth vehicle" in the years ahead. However, he said the hepatitis C virus (HCV) drug would nonetheless generate strong cash flow for years to come.